{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:34:48Z","timestamp":1788399288227,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T00:00:00Z","timestamp":1651449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["OPP1140599"],"award-info":[{"award-number":["OPP1140599"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the Republic of the Congo, malaria represents a major public health problem affecting all age groups. A regular surveillance of the current efficacy of first-line anti-malarial drugs is required in the face of possible emergence and spread of artemisinin-resistant <jats:italic>Plasmodium falciparum<\/jats:italic> strains in Africa. The purpose of this study was to determine the prevalence of malaria among febrile patients of all ages and assess the efficacy of artemether-lumefantrine (AL) and artesunate-amodiaquine (ASAQ) in Congolese children.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Febrile patients of all ages were initially screened for malaria by both rapid diagnostic test (RDT) and microscopy. Patients less than 12\u00a0years of age, with parasitaemia\u2009\u2265\u20091000 asexual parasites of <jats:italic>P. falciparum<\/jats:italic>\/\u00b5L of blood, without any signs of severity, were enrolled in a therapeutic efficacy study and treated after obtaining their parents' (or legal guardian\u2019s) informed consent in two health centres in Dolisie. The patients were followed for 28\u00a0days in accordance with the 2009 World Health Organization standard protocol. If parasitaemia reappeared on or after day 7, the genetic profiles (genes expressing merozoite surface protein-1 [<jats:italic>msp1<\/jats:italic>], merozoite surface protein-2 [<jats:italic>msp2<\/jats:italic>], and glutamine-rich protein [<jats:italic>glurp<\/jats:italic>]) of pre-treatment and post-treatment isolates were compared by nested polymerase chain reaction (PCR) followed by capillary electrophoresis to make a distinction between recrudescence and re-infection. The clinical and parasitological outcome was analysed by the per-protocol method and Kaplan\u2013Meier survival curves.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 994 febrile patients of all ages were screened by RDT and microscopy. Of 994 patients, 323 (32.5%) presented a positive RDT, and 266 (26.8%) were microscopy-positive. Based on microscopy as the reference diagnostic method, the sensitivity and the specificity of the RDT were 98.9 and 91.8%, respectively. The Cohen\u2019s kappa coefficient was 0.86. A total of 121 children aged less than 12\u00a0years (61 in AL treatment group and 60 in ASAQ treatment group) were included in therapeutic efficacy study. Before PCR correction, the proportions of adequate clinical and parasitological response were 96.6% for AL and 86.0% for ASAQ in the per-protocol population (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.05). The PCR-corrected efficacy rates were 98.2% and 94.2% for AL and ASAQ, respectively (<jats:italic>P<\/jats:italic>\u2009&gt;\u20090.05). Both treatments were well tolerated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AL and ASAQ remain highly effective for the first-line treatment of uncomplicated <jats:italic>P. falciparum<\/jats:italic> malaria in Dolisie. Despite high efficacy of first- and second-line treatment, there is a continuing need to scale up effective malaria preventive interventions and vector control strategies in the country.<\/jats:p>\n                <jats:p><jats:italic>Trial Registration Number:<\/jats:italic> ACTRN12616001422415.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-022-04143-4","type":"journal-article","created":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T13:12:13Z","timestamp":1651497133000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prevalence of malaria among febrile patients and assessment of efficacy of artemether-lumefantrine and artesunate-amodiaquine for uncomplicated malaria in Dolisie, Republic of the Congo"],"prefix":"10.1186","volume":"21","clinical-trial-number":[{"clinical-trial-number":"actrn12616001422415","registry":"10.18810\/anzctr"}],"author":[{"given":"Brice","family":"Pembet Singana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prisca Nadine","family":"Casimiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brunelle","family":"Matondo Diassivi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon Charles","family":"Kobawila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Mermoz","family":"Youndouka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8812-8185","authenticated-orcid":false,"given":"Leonardo K.","family":"Basco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Ringwald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Briolant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Ndounga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,2]]},"reference":[{"key":"4143_CR1","volume-title":"World malaria report","author":"WHO","year":"2020","unstructured":"WHO. World malaria report. Geneva: World Health Organization; 2020."},{"key":"4143_CR2","volume-title":"Programme biennal de d\u00e9veloppement sanitaire 2015\u20132016: document de mise en \u0153uvre du PND 2012\u20132016 dans le secteur de la sant\u00e9","author":"Minist\u00e8re de la Sant\u00e9 et de la Population","year":"2014","unstructured":"Minist\u00e8re de la Sant\u00e9 et de la Population. Programme biennal de d\u00e9veloppement sanitaire 2015\u20132016: document de mise en \u0153uvre du PND 2012\u20132016 dans le secteur de la sant\u00e9. Brazzaville: R\u00e9publique du Congo, Minist\u00e8re de la Sant\u00e9 et de la Population; 2014."},{"key":"4143_CR3","first-page":"239","volume":"3","author":"S Maberti","year":"1960","unstructured":"Maberti S. [The development of resistance to pyrimethamine. Presentation of 15 cases studied in Trujillo, Venezuela] (in Spanish). Arch Venez Med Trop Parasitol Med. 1960;3:239\u201359.","journal-title":"Arch Venez Med Trop Parasitol Med."},{"key":"4143_CR4","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(65)90395-8","volume":"2","author":"T Harinasuta","year":"1965","unstructured":"Harinasuta T, Suntharasamai P, Viravan C. Chloroquine-resistant falciparum malaria in Thailand. Lancet. 1965;2:657\u201360.","journal-title":"Lancet"},{"key":"4143_CR5","first-page":"309","volume":"18","author":"AWA Brown","year":"1958","unstructured":"Brown AWA. The insecticide-resistance problem: a review of developments in 1956 and 1957. Bull World Health Organ. 1958;18:309\u201321.","journal-title":"Bull World Health Organ"},{"key":"4143_CR6","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0163-7258(91)90074-V","volume":"50","author":"WH Wernsdorfer","year":"1991","unstructured":"Wernsdorfer WH, Payne D. The dynamics of drug resistance in Plasmodium falciparum. Pharmacol Ther. 1991;50:95\u2013121.","journal-title":"Pharmacol Ther"},{"key":"4143_CR7","first-page":"490","volume":"79","author":"B Carme","year":"1986","unstructured":"Carme B, Benthein F, Moudzeo H, Bitsi A, Madzou G. [Drug resistance of Plasmodium falciparum in Congo. I. In vivo study with 10 and 25 mg\/kg of chloroquine (235 tests)] (in French). Bull Soc Pathol Exot. 1986;79:490\u2013502.","journal-title":"Bull Soc Pathol Exot."},{"key":"4143_CR8","volume-title":"Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996\u20132004","author":"WHO","year":"2005","unstructured":"WHO. Susceptibility of Plasmodium falciparum to antimalarial drugs. Report on global monitoring 1996\u20132004. Geneva: World Health Organization; 2005."},{"key":"4143_CR9","doi-asserted-by":"publisher","first-page":"133","DOI":"10.4269\/ajtmh.2004.70.133","volume":"70","author":"B Nsimba","year":"2004","unstructured":"Nsimba B, Malonga DA, Mouata AM, Louya F, Kiori J, Malanda M, et al. Efficacy of sulfadoxine\/pyrimethamine in the treatment of uncomplicated Plasmodium falciparum malaria in Republic of Congo. Am J Trop Med Hyg. 2004;70:133\u20138.","journal-title":"Am J Trop Med Hyg"},{"key":"4143_CR10","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.actatropica.2007.06.002","volume":"103","author":"M Ndounga","year":"2007","unstructured":"Ndounga M, Mayengue PI, Tahar R, Casimiro PN, Matondo Maya DW, Miakassissa-Mpassi V, et al. Efficacy of sulfadoxine-pyrimethamine, amodiaquine, and sulfadoxine-pyrimethamine-amodiaquine combination for the treatment of uncomplicated falciparum malaria in the urban and suburban areas of Brazzaville (Congo). Acta Trop. 2007;103:163\u201371.","journal-title":"Acta Trop"},{"key":"4143_CR11","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1111\/j.1365-3156.2007.01904.x","volume":"12","author":"M Ndounga","year":"2007","unstructured":"Ndounga M, Tahar R, Basco LK, Casimiro PN, Malonga DA, Ntoumi F. Therapeutic efficacy of sulfadoxine-pyrimethamine and the prevalence of molecular markers of resistance in under 5-year olds in Brazzaville. Congo Trop Med Int Health. 2007;12:1164\u201371.","journal-title":"Congo Trop Med Int Health"},{"key":"4143_CR12","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1111\/j.1365-3156.2005.01490.x","volume":"10","author":"B Nsimba","year":"2005","unstructured":"Nsimba B, Jafari-Guemouri S, Malonga DA, Mouata AM, Kiori J, Louya F, et al. Epidemiology of drug-resistant malaria in Republic of Congo: using molecular evidence for monitoring antimalarial drug resistance combined with assessment of antimalarial drug use. Trop Med Int Health. 2005;10:1030\u20137.","journal-title":"Trop Med Int Health"},{"key":"4143_CR13","doi-asserted-by":"publisher","first-page":"2404","DOI":"10.1128\/JCM.00623-06","volume":"44","author":"B Pradines","year":"2006","unstructured":"Pradines B, Hovette P, Fusai T, Atanda HL, Baret E, Cheval P, et al. Prevalence of in vitro resistance to eleven standard or new antimalarial drugs among Plasmodium falciparum isolates from Pointe-Noire, Republic of the Congo. J Clin Microbiol. 2006;44:2404\u20138.","journal-title":"J Clin Microbiol"},{"key":"4143_CR14","volume-title":"Antimalarial drug combination therapy. WHO\/CDS\/RBM\/2001.35","author":"WHO","year":"2001","unstructured":"WHO. Antimalarial drug combination therapy. WHO\/CDS\/RBM\/2001.35. Geneva: World Health Organization; 2001."},{"key":"4143_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/1475-2875-5-113","volume":"5","author":"I Van de Broek","year":"2006","unstructured":"Van de Broek I, Kitz C, Al Attas S, Libama F, Balasegaram M, Guthmann JP. Efficacy of three artemisinin combination therapies for the treatment of uncomplicated Plasmodium falciparum malaria in the Republic of Congo. Malar J. 2006;5:113.","journal-title":"Malar J"},{"key":"4143_CR16","volume-title":"Methods for surveillance of antimalarial drug efficacy","author":"WHO","year":"2009","unstructured":"WHO. Methods for surveillance of antimalarial drug efficacy. Geneva: World Health Organization; 2009."},{"key":"4143_CR17","first-page":"749479","volume":"2012","author":"M Ndounga","year":"2012","unstructured":"Ndounga M, Tahar R, Casimiro PN, Loumouamou D, Basco LK. Clinical efficacy of artemether-lumefantrine in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar Res Treat. 2012;2012:749479.","journal-title":"Malar Res Treat."},{"key":"4143_CR18","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/1475-2875-12-53","volume":"12","author":"M Ndounga","year":"2013","unstructured":"Ndounga M, Mayengue PI, Casimiro PN, Loumouamou D, Basco LK, Ntoumi F, et al. Artesunate-amodiaquine efficacy in Congolese children with acute uncomplicated falciparum malaria in Brazzaville. Malar J. 2013;12:53.","journal-title":"Malar J"},{"key":"4143_CR19","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/s12936-015-0918-6","volume":"14","author":"M Ndounga","year":"2015","unstructured":"Ndounga M, Mayengue PI, Casimiro PN, Koukouikila-Koussounda F, Bitemo M, Matondo BD, et al. Artesunate-amodiaquine versus artemether-lumefantrine for the treatment of acute uncomplicated malaria in Congolese children under 10 years old living in a suburban area: a randomized study. Malar J. 2015;14:423.","journal-title":"Malar J"},{"key":"4143_CR20","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/s12936-015-1078-4","volume":"15","author":"BP Singana","year":"2016","unstructured":"Singana BP, Bogreau H, Matondo BD, Dossou-Yovo LR, Casimiro PN, Mbouka R, et al. Malaria burden and anti-malarial drug efficacy in Owando, northern Congo. Malar J. 2016;15:16.","journal-title":"Malar J"},{"key":"4143_CR21","volume-title":"Historical dictionary of Republic of the Congo","author":"JF Clark","year":"2012","unstructured":"Clark JF, Decalo S. Historical dictionary of Republic of the Congo. 4th ed. Lanham: Scarecrow Press, Inc.; 2012.","edition":"4"},{"key":"4143_CR22","unstructured":"PopulationData.net. 2017. https:\/\/en.populationdata.net\/countries\/congo\/ Accessed 06 Jan 2021."},{"key":"4143_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00704-007-0298-0","volume":"91","author":"G Samba","year":"2008","unstructured":"Samba G, Nganga D, Mpounza M. Rainfall and temperature variations over Congo-Brazzaville between 1950 and 1998. Theor Appl Climatol. 2008;91:85\u201397.","journal-title":"Theor Appl Climatol"},{"key":"4143_CR24","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1186\/s12936-016-1617-7","volume":"15","author":"F Koukouikila-Koussounda","year":"2016","unstructured":"Koukouikila-Koussounda F, Ntoumi F. Malaria epidemiological research in the Republic of Congo. Malar J. 2016;15:598.","journal-title":"Malar J"},{"key":"4143_CR25","unstructured":"Research malaria microscopy standards working group. Microscopy for the detection, identification and quantification of malaria parasites on stained thick and thin films. Geneva: World Health Organization, 2015. https:\/\/apps.who.int\/iris\/handle\/10665\/163782."},{"key":"4143_CR26","unstructured":"WHO. Methods and techniques for clinical trials on antimalarial drug efficacy: genotyping to identify parasite populations. Geneva: World Health Organization; 2008. https:\/\/www.who.int\/malaria\/publications\/atoz\/9789241596305\/en\/"},{"key":"4143_CR27","doi-asserted-by":"publisher","first-page":"e00590","DOI":"10.1128\/AAC.00590-19","volume":"63","author":"S Jones","year":"2019","unstructured":"Jones S, Kay K, Hodel EM, Chy S, Mbituyumuremyi A, Uwimana A, et al. Improving methods for analyzing antimalarial drug efficacy trials: molecular correction based on length-polymorphic markers msp-1, msp-2, and glurp. Antimicrob Agents Chemother. 2019;63:e00590-e619.","journal-title":"Antimicrob Agents Chemother"},{"key":"4143_CR28","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1177\/001316446002000104","volume":"20","author":"J Cohen","year":"1960","unstructured":"Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37\u201346.","journal-title":"Educ Psychol Meas"},{"key":"4143_CR29","doi-asserted-by":"publisher","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33:159\u201374.","journal-title":"Biometrics"},{"key":"4143_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2458-13-135","volume":"13","author":"F Ntoumi","year":"2013","unstructured":"Ntoumi F, Vouvoungui JC, Ibara R, Landry M, Sidib\u00e9 A. Malaria burden and case management in the Republic of Congo: limited use and application of rapid diagnostic tests results. BMC Public Health. 2013;13:135.","journal-title":"BMC Public Health"},{"key":"4143_CR31","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1111\/tmi.12786","volume":"21","author":"MK Etoka-Beka","year":"2016","unstructured":"Etoka-Beka MK, Ntoumi F, Kombo M, Deibert J, Poulain P, Vouvoungui C, et al. Plasmodium falciparum infection in febrile Congolese children: prevalence of clinical malaria 10 years after introduction of artemisinin-combination therapies. Trop Med Int Health. 2016;21:1496\u2013503.","journal-title":"Trop Med Int Health"},{"key":"4143_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1186\/s12936-017-1816-x","volume":"16","author":"F Koukouikila-Koussounda","year":"2017","unstructured":"Koukouikila-Koussounda F, Jeyaraj S, Nguetse CN, Nkonganyi CN, Kokou KC, Etoka-Beka MK, et al. Molecular surveillance of Plasmodium falciparum drug resistance in the Republic of Congo: four and nine years after the introduction of artemisinin-based combination therapy. Malar J. 2017;16:155.","journal-title":"Malar J"},{"key":"4143_CR33","doi-asserted-by":"crossref","unstructured":"Gueye NSG, Ntoumi F, Vouvoungui C, Kobawila SC, NKombo M, Mouanga AM, et al. Plasmodium falciparum merozoite protein-1 genetic diversity and multiplicity of infection in isolates from Congolese children consulting in a pediatric hospital in Brazzaville. Acta Trop. 2018;183:78\u201383.","DOI":"10.1016\/j.actatropica.2018.04.012"},{"key":"4143_CR34","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1186\/s12879-018-3453-6","volume":"18","author":"PI Mayengue","year":"2018","unstructured":"Mayengue PI, Niama RF, Batsimba DK, Malonga-Massanga A, Louzolo I, Bongolo NCL, et al. No polymorphisms in K13-propeller gene associated with artemisinin resistance in Plasmodium falciparum isolated from Brazzaville, Republic of Congo. BMC Infect Dis. 2018;18:538.","journal-title":"BMC Infect Dis"},{"key":"4143_CR35","doi-asserted-by":"publisher","first-page":"329","DOI":"10.3185\/pathexo3111","volume":"101","author":"M Ndounga","year":"2008","unstructured":"Ndounga M, Casimiro PN, Miakassissa-Mpassi V, Loumouamou D, Ntoumi F, Basco LK. [Malaria in health centres in the southern districts of Brazzaville, Congo](in French). Bull Soc Pathol Exot. 2008;101:329\u201335.","journal-title":"Bull Soc Pathol Exot"},{"key":"4143_CR36","volume-title":"World malaria report 2010","author":"WHO","year":"2010","unstructured":"WHO. World malaria report 2010. Geneva: World Health Organization; 2010."},{"key":"4143_CR37","volume-title":"Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010","author":"WHO","year":"2010","unstructured":"WHO. Global report on antimalarial drug efficacy and drug resistance: 2000\u20132010. Geneva: World Health Organization; 2010."},{"key":"4143_CR38","volume-title":"Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019)","author":"WHO","year":"2020","unstructured":"WHO. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010\u20132019). Geneva: World Health Organization; 2020."},{"key":"4143_CR39","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1086\/444460","volume":"41","author":"A M\u00e5rtensson","year":"2005","unstructured":"M\u00e5rtensson A, Str\u00f6mberg J, Sisowath C, Msellem MI, Gil JP, Montgomery SM, et al. Efficacy of artesunate plus amodiaquine versus that of artemether-lumefantrine for the treatment of uncomplicated childhood Plasmodium falciparum malaria in Zanzibar, Tanzania. Clin Infect Dis. 2005;41:1079\u201386.","journal-title":"Clin Infect Dis"},{"key":"4143_CR40","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1016\/S0140-6736(05)66417-3","volume":"365","author":"TK Mutabingwa","year":"2005","unstructured":"Mutabingwa TK, Anthony D, Heller A, Hallett R, Ahmed J, Drakeley C, et al. Amodiaquine alone, amodiaquine+sulfadoxine-pyrimethamine, amodiaquine+artesunate, and artemether-lumefantrine for outpatient treatment of malaria in Tanzanian children: a four-arm randomised effectiveness trial. Lancet. 2005;365:1474\u201380.","journal-title":"Lancet"},{"key":"4143_CR41","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1371\/journal.pctr.0010007","volume":"1","author":"H Bukirwa","year":"2006","unstructured":"Bukirwa H, Yeka A, Kamya MR, Talisuna A, Banek K, Bakyaita N, et al. Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials. 2006;1:e7.","journal-title":"PLoS Clin Trials."},{"key":"4143_CR42","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1586\/eri.09.53","volume":"7","author":"GO Adjei","year":"2009","unstructured":"Adjei GO, Goka BQ, Binka F, Kurtzhals JA. Artemether-lumefantrine: an oral antimalarial for uncomplicated malaria in children. Expert Rev Anti Infect Ther. 2009;7:669\u201381.","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"Suppl 1","key":"4143_CR43","doi-asserted-by":"publisher","first-page":"P19","DOI":"10.1186\/1475-2875-13-S1-P19","volume":"13","author":"MT Bretscher","year":"2014","unstructured":"Bretscher MT, Griffin JT, Hugo P, Baker M, Ghani A, Okell L, et al. A comparison of the duration of post-treatment protection of artemether-lumefantrine, dihydroartemisinin-piperaquine and artesunate-amodiaquine for the treatment of uncomplicated malaria. Malar J. 2014;13(Suppl 1):P19.","journal-title":"Malar J"},{"key":"4143_CR44","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"4143_CR45","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12916-020-1494-3","volume":"18","author":"MT Bretscher","year":"2020","unstructured":"Bretscher MT, Dahal P, Griffin J, Stepniewska K, Bassat Q, Baudin E, et al. The duration of chemoprophylaxis against malaria after treatment with artesunate-amodiaquine and artemether-lumefantrine and the effects of pfmdr1 86Y and pfcrt 76T: a meta-analysis of individual patient data. BMC Med. 2020;18:47.","journal-title":"BMC Med"},{"key":"4143_CR46","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/1475-2875-9-56","volume":"9","author":"SY Whegang","year":"2010","unstructured":"Whegang SY, Tahar R, Foumane VN, Soula G, Gw\u00e9t H, Thalabard JC, et al. Efficacy of non-artemisinin- and artemisinin-based combination therapies for uncomplicated falciparum malaria in Cameroon. Malar J. 2010;9:56.","journal-title":"Malar J"},{"key":"4143_CR47","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.4269\/ajtmh.12-0290","volume":"88","author":"P Charle","year":"2013","unstructured":"Charle P, Berzosa P, de Lucio A, Raso J, NsengNchama G, Benito A. Artesunate\/amodiaquine malaria treatment for Equatorial Guinea (Central Africa). Am J Trop Med Hyg. 2013;88:1087\u201392.","journal-title":"Am J Trop Med Hyg"},{"key":"4143_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/1475-2875-13-9","volume":"13","author":"D Djall\u00e9","year":"2014","unstructured":"Djall\u00e9 D, Njuimo SP, Manirakiza A, Laganier R, Le Faou A, Rogier C. Efficacy and safety of artemether + lumefantrine, artesunate + sulphamethoxypyrazine-pyrimethamine and artesunate + amodiaquine and sulphadoxine-pyrimethamine + amodiaquine in the treatment of uncomplicated falciparum malaria in Bangui, Central African Republic: a randomized trial. Malar J. 2014;13:9.","journal-title":"Malar J"},{"key":"4143_CR49","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12936-014-0521-2","volume":"14","author":"AM Nji","year":"2015","unstructured":"Nji AM, Ali IM, Moyeh MN, Ngongang EO, Ekollo AM, Chedjou JP, et al. Randomized non-inferiority and safety trial of dihydroartemisin-piperaquine and artesunate-amodiaquine versus artemether-lumefantrine in the treatment of uncomplicated Plasmodium falciparum malaria in Cameroonian children. Malar J. 2015;14:27.","journal-title":"Malar J"},{"key":"4143_CR50","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1186\/s12936-016-1444-x","volume":"15","author":"M de Wit","year":"2016","unstructured":"de Wit M, Funk AL, Moussally K, Nkuba DA, Siddiqui R, Bil K, et al. In vivo efficacy of artesunate\u2013amodiaquine and artemether\u2013lumefantrine for the treatment of uncomplicated falciparum malaria: an open-randomized, non-inferiority clinical trial in South Kivu, Democratic Republic of Congo. Malar J. 2016;15:455.","journal-title":"Malar J"},{"key":"4143_CR51","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1186\/s12936-019-3015-4","volume":"18","author":"BR Adegbite","year":"2019","unstructured":"Adegbite BR, Edoa JR, Honkpehedji YJ, Zinsou FJ, Dejon-Agobe JC, Mbong-Ngwese M, et al. Monitoring of efficacy, tolerability and safety of artemether-lumefantrine and artesunate-amodiaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Lambar\u00e9n\u00e9, Gabon: an open-label clinical trial. Malar J. 2019;18:424.","journal-title":"Malar J"},{"key":"4143_CR52","doi-asserted-by":"publisher","first-page":"898","DOI":"10.2478\/s11686-019-00115-y","volume":"64","author":"JM Ndong Ngomo","year":"2019","unstructured":"Ndong Ngomo JM, OndzaghaMegnie GJ, MoutombiDitombi B, KoumbaLengongo JV, M\u2019Bondoukw\u00e9 NP, Offouga CL, et al. Persistence of high in vivo efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine as the first- and second-line treatments for uncomplicated Plasmodium falciparum malaria 10 years after their implementation in Gabon. Acta Parasitol. 2019;64:898\u2013902.","journal-title":"Acta Parasitol"},{"key":"4143_CR53","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","volume":"14","author":"WWARN Gametocyte Study Group","year":"2016","unstructured":"WWARN Gametocyte Study Group. Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data. BMC Med. 2016;14:79.","journal-title":"BMC Med"},{"key":"4143_CR54","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1093\/cid\/cix336","volume":"65","author":"MM Ippolito","year":"2017","unstructured":"Ippolito MM, Johnson J, Mullin C, Mallow C, Morgan N, Wallender E, et al. The relative effects of artemether-lumefantrine and non-artemisinin antimalarials on gametocyte carriage and transmission of Plasmodium falciparum: a systematic review and meta-analysis. Clin Infect Dis. 2017;65:486\u201394.","journal-title":"Clin Infect Dis"},{"key":"4143_CR55","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/nature12876","volume":"505","author":"F Ariey","year":"2014","unstructured":"Ariey F, Witkowski B, Amaratunga C, Beghain J, Langlois AC, Khim N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50\u20135.","journal-title":"Nature"},{"key":"4143_CR56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jgar.2018.08.003","volume":"14","author":"DF Voumbo-Matoumona","year":"2018","unstructured":"Voumbo-Matoumona DF, Akiana J, Madamet M, Kouna LC, Lekana-Douki JB, Pradines B. High prevalence of Plasmodium falciparum antimalarial drug resistance markers in isolates from asymptomatic patients from the Republic of the Congo between 2010 and 2015. J Glob Antimicrob Resist. 2018;14:277\u201383.","journal-title":"J Glob Antimicrob Resist"},{"key":"4143_CR57","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1056\/NEJMc0805011","volume":"359","author":"H Noedl","year":"2008","unstructured":"Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619\u201320.","journal-title":"N Engl J Med"},{"key":"4143_CR58","doi-asserted-by":"publisher","first-page":"1602","DOI":"10.1038\/s41591-020-1005-2","volume":"26","author":"A Uwimana","year":"2020","unstructured":"Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26:1602\u20138.","journal-title":"Nat Med"},{"key":"4143_CR59","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2101746","volume":"385","author":"B Balikagala","year":"2021","unstructured":"Balikagala B, Fukuda N, Ikeda M, Katuro OT, Tachibana SI, Yamauchi M, et al. Evidence of artemisinin-resistant malaria in Africa. N Engl J Med. 2021;385:1163\u201371.","journal-title":"N Engl J Med"},{"key":"4143_CR60","doi-asserted-by":"publisher","first-page":"857","DOI":"10.4269\/ajtmh.21-0797","volume":"105","author":"PJ Rosenthal","year":"2021","unstructured":"Rosenthal PJ. Are artemisinin-based combination therapies for malaria beginning to fail in Africa? Am J Trop Med Hyg. 2021;105:857\u20138.","journal-title":"Am J Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-022-04143-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-022-04143-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,2]],"date-time":"2022-05-02T14:26:02Z","timestamp":1651501562000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-022-04143-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,2]]},"references-count":60,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["4143"],"URL":"https:\/\/doi.org\/10.1186\/s12936-022-04143-4","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,2]]},"assertion":[{"value":"21 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was reviewed and approved by the institutional ethics committee of research in health science (Comit\u00e9 d\u2019Ethique de la Recherche en Sciences de la Sant\u00e9, [CERSSA]) of the Congolese Ministry of Research and Ministry of Health and Population and the Ethical Review Committee of the WHO. Before enrolment of children in the cohort, their parents were informed about the objectives of the study, benefits, and constraints associated with participation in the study in French or in one of the two national languages (Lingala or Kituba). Parents or legal guardians who agreed to participate in the study signed the informed consent form.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"137"}}